Gemcitabine-Induced Hemolytic Uremic Syndrome in Lung Cancer: A Case Report

Gemcitabine is a broad-spectrum anti-metabolite drug that is widely used in the therapy of numerous advanced cancers such as pancreatic, breast, ovary, lung, and bladder cancer. Gemcitabine has been reported to cause hemolytic uremic syndrome (HUS), but the underlying mechanism is not elucidated. Th...

Descripción completa

Detalles Bibliográficos
Autores principales: Ahlawat, Prashant, Gupta, Monica, Upadhyay, Prateek, Gupta, Shivani, Kaur, Amanjot
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cureus 2022
Materias:
Internal Medicine
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8812056/
https://www.ncbi.nlm.nih.gov/pubmed/35145816
http://dx.doi.org/10.7759/cureus.20926

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8812056/
https://www.ncbi.nlm.nih.gov/pubmed/35145816
http://dx.doi.org/10.7759/cureus.20926

Ejemplares similares